Ownership and insider activity for Immunocore Holdings plc (IMCR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders.
Price
| Price | $31.59 |
| Market Cap | $1.6B |
| Exchange | NASDAQ |
| Country | GB |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-27 | Ratcliffe Peter John | A-Award | 27,492 | $784K |
| 2026-05-27 | Peterson Kristine | A-Award | 27,492 | $784K |
| 2026-05-27 | Pao William | A-Award | 27,492 | $784K |
| 2026-05-27 | Kaul Siddharth | A-Award | 27,492 | $784K |
| 2026-05-27 | Herbst Roy Steven | A-Award | 27,492 | $784K |
| 2026-05-27 | Bell John Irving | A-Award | 27,492 | $784K |
| 2026-02-17 | Coy Travis Alan | A-Award | 95,637 | $3.1M |
| 2026-02-17 | Coy Travis Alan | A-Award | 33,353 | |
| 2026-02-17 | Jallal Bahija | A-Award | 395,066 | $12.8M |
| 2026-02-17 | Jallal Bahija | A-Award | 88,573 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $134.3M | $84.0M | $124.4M | $98.0M | $176.8M | $321.1M | $402.5M | $350.3M | $455.7M | $467.7M |
| Short-term Investments | $42.2M | $34.6M | 0 | 0 | 0 | 0 | 0 | 0 | $364.6M | $396.4M |
| Receivables | $429812 | $4053 | $4.4M | $66.3M | $2.1M | $33.5M | $57.1M | $48.6M | $83.1M | $74.0M |
| Inventory | 0 | 0 | -$7.6M | 0 | -$6.5M | 0 | $692000 | $3.6M | $5.4M | $6.7M |
| Total Current Assets | $191.1M | $145.4M | $171.2M | $164.6M | $152.9M | $354.6M | $474.0M | $418.5M | $929.9M | $996.7M |
| Property, Plant & Equipment | $11.1M | $24.2M | $20.9M | $72.7M | $36.8M | $42.6M | $38.8M | $33.8M | $47.7M | $50.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $371837 | $742776 | $318000 | 0 | 0 | 0 | $410 | 0 | 0 | 0 |
| Total Assets | $219.1M | $198.0M | $195.8M | $245.9M | $197.2M | $407.3M | $526.8M | $472.4M | $1.01B | $1.07B |
| Accounts Payable | $3.1M | $8.1M | $6.4M | $20.8M | $7.9M | $10.1M | $14.4M | $14.1M | $25.1M | $24.4M |
| Short-term Debt | 0 | 0 | 0 | $28.0M | $9.8M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $21.8M | $30.2M | $49.6M | $112.0M | $55.0M | $82.6M | $100.8M | $110.0M | $212.2M | $246.7M |
| Long-term Debt | 0 | $17.2M | $18.9M | 0 | $36.7M | $50.2M | $47.8M | $38.0M | $391.0M | $393.1M |
| Total Liabilities | $44.1M | $60.5M | $139.2M | $226.4M | $141.8M | $175.8M | $187.9M | $180.6M | $648.8M | $686.2M |
| Retained Earnings | -$61.1M | -$111.5M | -$175.2M | -$369.7M | -$349.9M | -$649.7M | -$689.4M | -$589.3M | -$795.8M | -$831.3M |
| Total Equity | $175.0M | $137.5M | $56.6M | $19.6M | $55.3M | $231.5M | $338.9M | $291.9M | $360.7M | $381.0M |
| Total Debt | 0 | $17.2M | $18.9M | $78.7M | $74.5M | $86.2M | $81.4M | $66.5M | $432.7M | $436.7M |
| Net Debt | -$176.5M | -$101.4M | -$105.5M | -$19.3M | -$102.3M | -$234.9M | -$321.0M | -$283.8M | -$387.7M | -$427.5M |
| Working Capital | $169.3M | $115.2M | $121.6M | $52.7M | $97.9M | $272.0M | $373.1M | $308.5M | $717.7M | $750.0M |
Financial Health
| Debt / Equity | 1.04 |
| Current Ratio | 4.47 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 1.46 |
Profitability
| Return on Equity | -2.35% |
| Return on Invested Capital | 13.56% |
| Return on Assets | -0.83% |
| Gross Margin | 98.85% |
| Operating Margin | -4.33% |
| Net Margin | -2.31% |
Related companies: ABCL · BHVN · CLDX · HRMY · JANX · MNKD · NUVB
Explore sector: Healthcare · Biotechnology
More sections of IMCR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks